Navigation Links
Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
Date:10/30/2007

KENILWORTH, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Leading researchers will present 68 data presentations involving Schering-Plough's hepatitis products, including PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy, a current standard of care in the treatment of chronic hepatitis C, at the 58th American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Nov. 2-6.

Among these are several studies discussing the predictability of response with PEGINTRON and REBETOL and assessing how results at important treatment milestones early in the course of therapy can help physicians and patients make informed treatment decisions.

Researchers will present the final results from the POWeR (Peginterferon alfa-2b Prospective Optimal Weight-based Dosing Response) program, a large observational study involving nearly 2,000 patients conducted at academic and community clinics in Canada between 2002 and 2006. In the study, PEGINTRON and REBETOL combination therapy achieved consistent sustained virologic response (SVR) rates across patient weights and consistently low relapse rates in a "real-life" treatment setting.

Investigators also will present new data on the investigational use of low-dose PEGINTRON as maintenance therapy in chronic hepatitis C nonresponder patients with fibrosis or cirrhosis. The goal of maintenance therapy in this very hard-to-treat patient population is to prevent or delay the progression of liver disease.

Hepatitis C is the most common blood-borne infection in America and the most common form of liver disease, affecting nearly 5 million people in the United States and 200 million people worldwide.

For program information, please visit the American Association of Liver Disease Web site at http://www.aasld.org.

Key PEGINTRON Presentations:

Predictability of Response

Predictability of Response:
'/>"/>

SOURCE Schering-Plough
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
3. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
4. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
5. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
6. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
7. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
8. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
9. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
10. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
11. Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 2015  IRIDEX Corporation (Nasdaq: IRIX ) today ... granted the Company a patent for a new proprietary ... eye surgery. The iClip Closure Device will initially be ... a broader range of ophthalmic surgical procedures in the ... procedure used in the treatment of glaucoma to drain ...
(Date:3/29/2015)... , March 29, 2015  Three-month paliperidone palmitate, ... relapse compared to placebo in patients with schizophrenia, ... published this week in the Journal ... . Results of the study served ... Application (NDA) filing for three-month paliperidone palmitate injection ...
(Date:3/27/2015)... NEW YORK , March 27, 2015 ... of Ohr Pharmaceutical, Inc. (NASDAQ: OHRP ) concerning ... certain statements issued by the Company in connection with ... information, GO TO: http://zlk.9nl.com/ohr-pharmaceutical-ohrp or contact ... jlevi@zlk.com or by telephone at (212) 363-7500, ...
Breaking Medicine Technology:IRIDEX Granted U.S. Patent for Disposable Device for Efficient and Predictable Wound Closure in Eye Surgeries 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12
(Date:3/30/2015)... CA (PRWEB) March 30, 2015 ... promotion on Invisalign. Eligible patients will receive $200 off ... are not particularly interested in wearing a mouthful of ... team, “The use of traditional braces is effective for ... who are already concerned with their oral appearance. The ...
(Date:3/30/2015)... Valerie Harper, the actress best known as ... Mary Tyler Moore Show,” will be the keynote speaker ... magazine announced today. Harper, who is living with terminal ... 40th Annual Congress on April 23 in Orlando, Fla. ... play in the lives of people with cancer. Nominated ...
(Date:3/30/2015)... 2015 GenSight ®, provider of ... as a leader in The Forrester Wave™: Strategic Planning ... , The independent report positions GenSight as a leader ... out of 5) for the analytics, corporate strategy, assessment, ... to GenSight’s position in the Leaders category. , According ...
(Date:3/30/2015)... 30, 2015 In an email sent ... of Oak Ridge, TN Community Development Department, announced: “I ... to traditional LBP work”. , ECOBOND® ... lead paint solution and surpasses other lead paint products ... that seals and treats lead dust and lead in ...
(Date:3/30/2015)... Software applications from five global ... second AS4 test and certification event, announced today ... interoperability software testing. New software applications from Axway, ... in this vendor-neutral test event which began in ... certifications for IBM, Oracle and Software AG, joining ...
Breaking Medicine News(10 mins):Health News:Northridge Cosmetic Dentist, Dr. Arami, is Now Offering a New Promotion on Invisalign 2Health News:Spunky Sitcom Star and Lung Cancer Survivor Valerie Harper to Keynote Extraordinary Healer™ Award Ceremony Honoring Oncoloy Nurses 2Health News:Spunky Sitcom Star and Lung Cancer Survivor Valerie Harper to Keynote Extraordinary Healer™ Award Ceremony Honoring Oncoloy Nurses 3Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 3Health News:ECOBOND® Selected to Protect School Children in Oak Ridge Tennessee in Lead Based Paint Remediation Project. 2Health News:Latest AS4 Standard-Based Products Drummond Certified™ 2Health News:Latest AS4 Standard-Based Products Drummond Certified™ 3
... Award Recognizes Campaign to Vaccinate 1.2 Million Americans - ... and MinuteClinic, CVS Caremark,s retail clinic division, have received ... for a Corporate Campaign. The award, co-sponsored by ... Control and Prevention, was presented yesterday evening in Dallas ...
... found evidence that chronic disease in either a mother ... that are associated with the development of polycystic ovarian ... that brothers of women with PCOS and insulin resistance ... or diabetes, suggesting that factors associated with the condition ...
... Additional research is called for and patients with moderate ... to reduce their risk of atherosclerotic cardiovascular disease (CVD), ... The American Journal of Cardiology and ... issue of The American Journal of Cardiology ...
... CA, June 30 /PRNewswire-FirstCall/ - Canadian Bio Med Systems Inc., ... Inc. of San Diego California, announced the development of a ... Systems, Inc. (CBMS). , Age-Related Macular Degeneration (AMD) is the ... of age. The incidence of AMD in persons aged 55 ...
... FHCO ) today announced that it has been added ... Group reconstituted its comprehensive set of U.S. and global equity indexes ... Index is comprised of companies 1001 through 3000 within the ... cap companies. "We are very pleased to learn that The ...
... tackles lack of information about the disease in the Hispanic ... comic strip "Baldo" will feature a storyline on diabetes in ... disease among Hispanics. , The comic strip features a Hispanic ... will begin June 30, Baldo will learn his father has ...
Cached Medicine News:Health News:CVS/pharmacy and MinuteClinic Receive Award of Excellence from National Influenza Vaccine Summit 2Health News:CVS/pharmacy and MinuteClinic Receive Award of Excellence from National Influenza Vaccine Summit 3Health News:Polycystic ovarian syndrome: New light on its causes and its effect on brothers 2Health News:Polycystic ovarian syndrome: New light on its causes and its effect on brothers 3Health News:Polycystic ovarian syndrome: New light on its causes and its effect on brothers 4Health News:Patients with moderate to severe periodontitis need evaluation for heart disease risk 2Health News:Canadian Bio Med Attacks World's Leading Cause of Blindness 2Health News:The Female Health Company Added to Russell 2000(R) Index 2Health News:The Female Health Company Added to Russell 2000(R) Index 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: